CFDE Data Portal | Search GBA1LP

	Label	Description
	GBA1LP Gene (Entity type)	ENSG00000291137 - glucosylceramidase beta 1 like, pseudogene
	GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE139178 GDC-0068 3 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE150540 dipyridamole DPM HUVEC-C 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 4 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE99875 everolimus 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE143782 calcitriol 3 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE203329 HCC knockout 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE179235 MEK NRAS inhibition 2 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216540 fulvestrant 10 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS

GBA1LP

ENSG00000291137 - glucosylceramidase beta 1 like, pseudogene

GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up

A Gene Set from LINCS

GSE139178 GDC-0068 3 v 7 human up

A Gene Set from LINCS

GSE150540 dipyridamole DPM HUVEC-C 1 v 2 human up

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 4 v 0 human dn

A Gene Set from LINCS

GSE99875 everolimus 2 v 0 human dn

A Gene Set from LINCS

GSE143782 calcitriol 3 v 4 human up

A Gene Set from LINCS

GSE203329 HCC knockout 2 v 1 human up

A Gene Set from LINCS

GSE179235 MEK NRAS inhibition 2 v 6 human dn

A Gene Set from LINCS

GSE216540 fulvestrant 10 v 6 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.